Effect of atorvastatin on pulmonary hypertension in chronic pulmonary heart disease
10.3760/cma.j.issn.1008-6315.2012.07.001
- VernacularTitle:阿托伐他汀对慢性肺源性心脏病患者肺动脉高压的影响
- Author:
Haifeng LIU
;
Xuewen QI
;
Lihong SUN
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
Chronic pulmonary heart disease;
Pulmonary hypertension;
High sensitive C-reaction protein;
Interleukin-8
- From:
Clinical Medicine of China
2012;28(7):673-676
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and mechanism of atorvastatin on pulmonary hyper-tension in chronic pulmonary heart disease.Methods Sixty eight patients with chronic pulmonary heart disease were randomly divided into treatment group (n=35) and observation group ( n=33 ).Thirty healthy people were picked up from people taking physical examination at the same stage as control group.Patients in both treatment and observation groups were given routine treatment and the observation group were given atorvastatin (20 mg/d) supplement.Changes in pulmonary function,ultrasound cardiogram,plasma high-sensitive C-reactive protein (hs-CRP) and interleukin (IL-8) were observed before and after 6 months of treatment.Results The levels of hs-CRP,IL-8 and pulmonary arterial pressure in treatment and observation groups are higher than that in normal group before treatment (t=2.87,2.79,3.01,3.28,3.31,3.15,respectively,and P =0.005,0.007,0.004,0.001,0.001,0.002,respectively).The pulmonary arterial pressure,hs-CRP,IL-8 in observation group after treated for 6 months were significantly lower than those before treatment and in treatment group (t=2.17,2.59,2.63,1.91,1.86,1.74,respectively,and P =0.039,0.008,0.007,0.031,0.037,0.042,respectively).The pulmonary function indexes including FEV1 and FEV1/FVC in observation group were much better than those in treatment group after 6 months treatment (t=1.84,2.13,respectively,and =0.037,0.024,respectively).There were no significant differences on these indicators in treatment group after 6 months treatment when compared with before treatment ( P ＞ 0.05 ).Conclusion Atorvastatin can effectively improve the life quality and pulmonary function,decrease pulmonary arterial pressure of patients with chronic pulmonary heart disease.These effects may be related to the inhibition of inflammation in pulmonary vessels.
